Skip to main content

The mammography patent dispute between Hologic and Siemens Healthineers has moved to the United States: three days apart, the two manufacturers filed patent-infringement suits against each other in the U.S. District Court for the District of Delaware. Both cases turn on the same engineering idea, shifting the focal spot inside the X-ray tube to offset tube motion during digital breast tomosynthesis (DBT), and both are at the pleading stage, with no allegation yet tested by the court.

Siemens Medical Solutions USA filed first, on Nov. 13, 2026, targeting Hologic’s Envision platform. Hologic followed on Nov. 16 with a suit against the Mammomat B.brilliant. In June we reported Hologic’s win at the Unified Patent Court (UPC); this piece focuses on what has changed since.

Patient undergoing mammography assisted by a technologist in a breast imaging service
Illustrative mammography exam; the unit shown is not one of the systems named in the lawsuits. Photo: NCI/Rhoda Baer (public domain).

Europe: the sales ban stands while Siemens appeals

On June 10, 2026, the UPC’s Düsseldorf Local Division found that the B.brilliant infringes Hologic’s European patent EP 2 352 431, dismissed Siemens’ counterclaim for revocation, and barred sales of the system in Germany, France and the Netherlands, ordering recall and destruction of infringing units there, according to JUVE Patent.

Siemens appealed on June 11 and asked for suspensive effect, which would have frozen the ban pending appeal. In an order dated July 15, 2026 (UPC-CoA-93/2026), the UPC Court of Appeal refused: it found no manifest error in the claim construction and no breach of the right to be heard, and left the merits to the main appeal. The ban therefore remains enforceable. As of publication, we found no ruling on the merits.

What Hologic alleges against the Mammomat B.brilliant

In case 1:26-cv-01470, against Siemens Healthineers AG, Siemens Healthcare GmbH and Siemens Medical Solutions USA, Hologic alleges that the B.brilliant, including VA10 and VA11 software versions and its X-ray tubes, infringes five U.S. patents: 8,457,282; 8,515,005; 8,767,911; 9,502,148; and 9,895,115. All belong to one family claiming priority to a provisional application filed Nov. 24, 2008. The complaint describes the system using Siemens’ own statements: the tube sweeps continuously through 50°, the system acquires 25 projections, and during each pulse the electron beam is deflected so the focal spot moves opposite to the tube. We confirmed in the FDA database the two 510(k) clearances it cites: K233539, March 27, 2024, and K253678, June 18, 2026.

Hologic alleges willful infringement because Siemens has known of the corresponding European patent at least since 2019, when it unsuccessfully challenged it at the European Patent Office. The complaint concedes the U.S. claims must be judged “independently under United States law,” but argues the UPC case “is relevant to the parties’ history and to Siemens’ knowledge” of the technology. Hologic seeks damages of no less than a reasonable royalty, up to treble damages for willfulness, a permanent injunction on making, using, selling or importing the product in the U.S., and a jury trial.

Siemens’ suit: a former Philips patent aimed at Envision

In case 1:26-cv-01460, Siemens Medical Solutions USA accuses Hologic of infringing U.S. Patent 8,284,894, issued Oct. 9, 2012, naming Tiemen Poorter as inventor and originally owned by Koninklijke Philips. According to the complaint, Siemens Healthineers AG acquired it from Philips in an assignment recorded at the USPTO in July 2026, then moved it to its U.S. subsidiary in October.

Siemens frames the patent as a fix for a tomosynthesis trade-off: in “stop and shoot” acquisition the tube halts for each projection, lengthening the scan, while with continuous motion, focal-spot travel can blur the image. The claimed solution acquires projections during continuous rotation while the focal spot moves across the anode against the tube’s direction, which “produces motion-blur-free images in a shorter total acquisition time,” the complaint says. Siemens alleges that Envision, assembled by Hologic in Newark, Delaware, infringes at least claims 1 and 10, including through demonstrations such as its unveiling at RSNA in December 2024. To support willfulness, it says it notified Hologic by email on Aug. 13, 2026.

Siemens seeks an injunction, damages and a jury trial. In a statement to Radiology Business, the company said it “is prepared to vigorously defend its position using all legal means at its disposal” and remains “confident in the strength of our legal position.” Hologic had not responded to the outlet by the time of that report.

Why the moving focal spot sits at the center of the fight

In DBT, the tube travels along an arc and acquires low-dose projections that are reconstructed into thin breast slices, the same stack newer tools try to condense, such as AI-generated slabs that shorten DBT reading time. The faster the tube moves, the shorter the sweep, but the farther the source travels during each pulse, which enlarges the effective focal spot and blurs fine detail such as microcalcifications. Moving the focal spot electronically in the opposite direction makes it appear stationary relative to the breast and detector.

Both products use this approach, according to their makers: Siemens calls it a flying focal spot; Hologic calls its version Focusing Technology and advertises a 2.5-second 3D scan on Envision. The FDA approval for Envision (PMA P080003/S009, July 5, 2024) explicitly lists an X-ray source with a moving focal spot. An FDA Federal Register notice from November 2025 records that Hologic sought patent term extension, based on Envision, for three of the patents it now asserts (8,457,282; 8,767,911; and 9,895,115), and Siemens says its infringement case relies in part on the technical description tied to that request.

What it means for breast imaging providers

In the U.S., nothing changes right away: these are opening complaints, the defendants have not yet answered, and no injunction is in place. Only the manufacturers are defendants; hospitals, imaging centers, radiologists and technologists appear in the filings as users each company says the other induced, not as parties. In Europe the effect is already concrete in three countries, and the Düsseldorf court rejected a patient-interest argument by pointing to alternative systems on the market. Siemens told JUVE Patent the decision “does not concern the system’s performance or security.”

For buyers elsewhere, including in Latin America, patents are territorial: UPC or U.S. rulings have no direct effect outside their jurisdictions, where only locally granted rights would count, which this report did not check. Even so, a site evaluating a tomosynthesis purchase can review contract terms on supply continuity, parts, service and manufacturer responsibility in intellectual-property disputes. Equipment choice still rests on clinical performance, dose and workflow, issues that also run through the debate on whether screening ultrasound is still needed in the DBT era.

Limits of this report and what to watch

This article draws on the two complaints, which present only each plaintiff’s side, the UPC Court of Appeal order, FDA records, and coverage by Radiology Business, Bloomberg Law and JUVE Patent; the claim-chart exhibits were not available. Next milestones are the defendants’ responses in Delaware and the UPC appeal decisions.

Source: Radiology Business — Hologic and Siemens Healthineers trade patent-infringement lawsuits. Documents: Hologic complaint (D. Del., 1:26-cv-01470); Siemens complaint (D. Del., 1:26-cv-01460); UPC Court of Appeal order (July 15, 2026).